PMID- 35725420
OWN - NLM
STAT- MEDLINE
DCOM- 20220622
LR  - 20220716
IS  - 1471-2407 (Electronic)
IS  - 1471-2407 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Jun 20
TI  - A network meta-analysis for efficacies and toxicities of different concurrent 
      chemoradiotherapy regimens in the treatment of locally advanced non-small cell 
      lung cancer.
PG  - 674
LID - 10.1186/s12885-022-09717-8 [doi]
LID - 674
AB  - BACKGROUND: Concurrent chemoradiotherapy (CCRT) has become the cornerstone of 
      treatment for patients with locally advanced non-small cell lung cancer 
      (LA-NSCLC). The aim of this study was to compare the efficacies and toxicities of 
      different CCRT regimens in the treatment of LA-NSCLC by adopting a network 
      meta-analysis (NMA). METHODS: An exhaustive search of PubMed, EMBASE, Web of 
      Science, and the Cochrane Central Register of Controlled Trials (CENTRAL) was 
      conducted to identify relevant studies from inception to October 1, 2020. Direct 
      and indirect evidence was combined to calculate the odds radios (ORs) and 95% 
      confidence intervals (CIs), as well as to plot the surface under the cumulative 
      ranking (SUCRA) curves. Cluster analyses were adopted to compare the efficacies 
      and toxicities of different CCRT regimens according to the similarity of 2 
      variables. Publication bias was detected by comparison-adjusted funnel plots. 
      RESULTS: Twenty-two studies were enrolled in this NMA, including 18 regimens: 
      CCRT (cisplatin + etoposide), CCRT (carboplatin + paclitaxel), CCRT 
      (pemetrexed + carboplatin), CCRT (pemetrexed + cisplatin), CCRT 
      (docetaxel + cisplatin), CCRT (S-1 + cisplatin), CCRT 
      (mitomycin + vindesine + cisplatin), CCRT (cisplatin + vinorelbine), CCRT 
      (cisplatin), CCRT (etoposide + cisplatin + amifostine), RT, CCRT (5-FU), CCRT 
      (paclitaxel + cisplatin), CCRT (irinotecan + carboplatin), CCRT (nedaplatin), 
      CCRT (carboplatin + etoposide), CCRT (paclitaxel), and CCRT (carboplatin). The 
      results indicated that the regimens with CCRT (cisplatin + etoposide), CCRT 
      (carboplatin + paclitaxel), CCRT (pemetrexed + cisplatin), CCRT 
      (S-1 + cisplatin), and CCRT (cisplatin + vinorelbine) had relatively better 
      efficacies compared with other regimens. As for toxicities of different CCRT 
      regimens, the CCRT (carboplatin + paclitaxel), CCRT (pemetrexed + cisplatin), and 
      CCRT (docetaxel + cisplatin) were relatively lower. CONCLUSIONS: Our study 
      demonstrated that CCRT (pemetrexed + cisplatin) and CCRT 
      (carboplatin + paclitaxel) might be the best options for the treatment of 
      LA-NSCLC, and CCRT (pemetrexed + cisplatin) had the highest 3-year overall 
      survival (OS) rate.
CI  - (c) 2022. The Author(s).
FAU - Zheng, Qiangqiang
AU  - Zheng Q
AD  - Department of Thoracic Surgery, West China School of Public Health and West China 
      Fourth Hospital, Sichuan University, Chengdu, Sichuan, 610044, People's Republic 
      of China.
FAU - Min, Shihui
AU  - Min S
AD  - Department of Oncology, West China School of Public Health and West China Fourth 
      Hospital, Sichuan University, Chengdu, Sichuan, 610044, People's Republic of 
      China.
FAU - Zhou, Yunfeng
AU  - Zhou Y
AUID- ORCID: 0000-0002-9785-2378
AD  - Department of Thoracic Surgery, West China School of Public Health and West China 
      Fourth Hospital, Sichuan University, Chengdu, Sichuan, 610044, People's Republic 
      of China. yunf_zhou_hxsy@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20220620
PL  - England
TA  - BMC Cancer
JT  - BMC cancer
JID - 100967800
RN  - 04Q9AIZ7NO (Pemetrexed)
RN  - 15H5577CQD (Docetaxel)
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 7673326042 (Irinotecan)
RN  - BG3F62OND5 (Carboplatin)
RN  - P88XT4IS4D (Paclitaxel)
RN  - Q20Q21Q62J (Cisplatin)
RN  - Q6C979R91Y (Vinorelbine)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
MH  - Carboplatin
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy/etiology
MH  - Chemoradiotherapy/adverse effects/methods
MH  - Cisplatin/adverse effects
MH  - Docetaxel/therapeutic use
MH  - Etoposide/therapeutic use
MH  - Humans
MH  - Irinotecan/therapeutic use
MH  - *Lung Neoplasms/drug therapy/etiology
MH  - Network Meta-Analysis
MH  - Paclitaxel
MH  - Pemetrexed/therapeutic use
MH  - Vinorelbine
PMC - PMC9208126
OTO - NOTNLM
OT  - Concurrent chemoradiotherapy
OT  - Efficacy
OT  - Locally advanced non-small cell lung cancer
OT  - Network meta-analysis
OT  - Randomized controlled trial
OT  - Toxicity
COIS- None of the authors have potential competing interests with this manuscript.
EDAT- 2022/06/21 06:00
MHDA- 2022/06/23 06:00
PMCR- 2022/06/20
CRDT- 2022/06/20 23:34
PHST- 2021/01/11 00:00 [received]
PHST- 2022/05/30 00:00 [accepted]
PHST- 2022/06/20 23:34 [entrez]
PHST- 2022/06/21 06:00 [pubmed]
PHST- 2022/06/23 06:00 [medline]
PHST- 2022/06/20 00:00 [pmc-release]
AID - 10.1186/s12885-022-09717-8 [pii]
AID - 9717 [pii]
AID - 10.1186/s12885-022-09717-8 [doi]
PST - epublish
SO  - BMC Cancer. 2022 Jun 20;22(1):674. doi: 10.1186/s12885-022-09717-8.